Response to Axicabtagene Ciloleucel Superior to Standard Care in R/R Large B-Cell Lymphoma
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Diagnosis & Disease Information
Allo-HSCT: Unrelated, Haploidentical Donations May Yield Similar Outcomes
No differences were noted in rates of grade 2 to 4 acute graft-versus-host disease, non-relapse mortality, or relapse risk.
Pembrolizumab May Improve Responses to Consolidation in Pediatric Classic Hodgkin Lymphoma
Researchers sought to determine whether adding pembrolizumab to consolidation chemotherapy would be effective in pediatric patients with high-risk classic Hodgkin lymphoma.
Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Dara-KRD Induction Effective in High-Risk, Newly Diagnosed Myeloma
The rate of minimal residual disease negativity was 62% after induction.
Long-Term Prophylaxis Cost-Effective for Von Willebrand Disease
Researchers sought to determine whether long-term prophylaxis against bleeds in patients with von Willebrand disease would be cost effective.
Triplet Maintenance After HSCT Improves PFS vs Lenalidomide Alone in Multiple Myeloma
Results of the phase 3 ATLAS trial revealed a potential new standard of care, according to researchers.
Patients With Polycythemia Vera Achieve Long-Term Treatment Goals With Ropeginterferon Alfa-2b
Researchers sought to determine whether long-term ropeginterferon alfa-2b would have benefits in patients with PV compared with hydroxyurea or the best available treatment.
Eculizumab Biosimilar Appears Effective in Paroxysmal Nocturnal Hemoglobinuria
Researchers sought to determine whether SB12 would be a clinical equivalent to eculizumab for improving lactate dehydrogenase levels in patients with PNH.
Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis
Momelotinib proved superior to danazol in patients with symptomatic, anemic myelofibrosis in a phase 3 study.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...